Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Aytu BioScience ( (AYTU) ) is now available.
On June 20, 2025, Aytu BioPharma, Inc. expanded and extended its lending agreement with Eclipse Business Capital LLC to provide added working capital flexibility in anticipation of the commercial launch of EXXUA™ in late 2025. This agreement includes extending the term loan maturity to June 2029, increasing the principal balance to $13.0 million, and expanding the revolving credit facility by $1.5 million. EXXUA, a novel antidepressant, is expected to enter the over $22 billion U.S. prescription MDD market, addressing significant unmet needs due to its favorable side effect profile demonstrated in clinical trials.
The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.
Spark’s Take on AYTU Stock
According to Spark, TipRanks’ AI Analyst, AYTU is a Neutral.
Aytu BioScience shows strong potential with positive earnings call outcomes and corporate events. However, financial performance and valuation concerns limit the overall score. Technical analysis provides a positive outlook, but core financial challenges must be addressed.
To see Spark’s full report on AYTU stock, click here.
More about Aytu BioScience
Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The company’s prescription products include EXXUA™ for major depressive disorder, Adzenys XR-ODT® for ADHD, and a line of legacy products such as Karbinal® ER.
Average Trading Volume: 1,395,335
Technical Sentiment Signal: Sell
Current Market Cap: $12.34M
Learn more about AYTU stock on TipRanks’ Stock Analysis page.